Overview: Glucagon TestIntroduction: The Glucagon Test measures glucagon levels to diagnose pancreatic disorders, causing weight loss or diabetes. Following 2023 ADA guidelines, it uses an immunoassay for high sensitivity, aiding in endocrine screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in endocrinology for patients with suspected pancreatic disorders. It helps differentiate conditions like glucagonoma or diabetes-related pancreatic dysfunction, supporting targeted therapy.
Other Names: Glucagon Assay, Pancreatic Hormone Test.
FDA Status: Laboratory-developed test (LDT), meeting endocrinology standards for diagnostic accuracy.
Historical Milestone: Glucagon testing began in the 1970s with pancreatic research. Immunoassays emerged in the 1990s, improving accuracy for endocrine disorders, with further refinements in the 2000s.
Purpose: Diagnoses pancreatic disorders, guides treatment, and monitors glucagon levels in patients with weight loss, diabetes, or hypoglycemia.
Test Parameters: 1. Glucagon
Pretest Condition: Fasting for 10-12 hours required to stabilize glucagon levels. Collect plasma or serum in the morning. Report symptoms like weight loss, diabetes, or hypoglycemia, and list medications.
Specimen: 2-4 mL plasma (EDTA) or 2-5 mL serum (SST). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document weight loss, diabetes, hypoglycemia, or history of pancreatic disorders. Include current medications, especially antidiabetics or insulin.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for pancreatic treatment or monitoring.
Procedural Considerations: Uses an immunoassay to measure glucagon levels. Results are available in 1-2 days, enabling rapid clinical decisions. Performed in laboratories, often paired with other endocrine tests.
Factors Affecting Result Accuracy: Non-fasting, hemolysis, or medications (e.g., insulin, stress hormones) can affect results. Stress or liver disease may alter levels, requiring careful interpretation.
Clinical Significance: Abnormal glucagon levels suggest pancreatic disorders (e.g., glucagonoma), prompting further testing or treatment. Normal levels may require additional evaluation to rule out other causes.
Specialist Consultation: Consult an endocrinologist for result interpretation and management planning.
Additional Supporting Tests: C-peptide, insulin levels, HbA1c, or pancreatic imaging (e.g., CT) to confirm pancreatic disorders.
Test Limitations: Stress, medications, or non-pancreatic conditions may affect levels. Results require clinical correlation for accurate diagnosis.
References: ADA Pancreatic Guidelines, 2023; Diabetes Care, Nathan DM, 2022.
